The distribution of Atherosclerosis Market Share is characterized by intense competition among global pharmaceutical giants who vie for dominance across the diverse therapeutic segments, from high-volume generics to premium-priced biologics. The largest collective share of the market is held by manufacturers of lipid-lowering therapies, particularly those who maintain patent exclusivity or possess a dominant generic manufacturing capacity for key statins (e.g., Atorvastatin, Simvastatin) and non-statin agents (e.g., Ezetimibe). Companies with a broad portfolio spanning multiple drug classes (including antiplatelets and ACE inhibitors) possess a crucial competitive advantage by offering comprehensive solutions across the continuum of care, from prevention to post-event management.

The fastest-growing share, however, is being captured by manufacturers who pioneered or quickly adopted novel injectable biologics, specifically the PCSK9 inhibitors. Companies like Amgen and Sanofi/Regeneron have carved out a high-value share by targeting patients with high residual cardiovascular risk or familial hypercholesterolemia, segments where these premium-priced drugs offer unparalleled LDL-C reduction. Furthermore, the market share distribution is significantly influenced by the interventional cardiology segment, where medical device companies (e.g., Abbott, Medtronic) hold substantial share through their sales of high-performance drug-eluting stents and other revascularization devices. The distribution channel is another critical factor: while retail and mail-order pharmacies handle the high volume of oral medication, the hospital and specialty pharmacy channels control the high-cost injectable and procedural segments, meaning manufacturers must secure strong presence in both to maximize their overall market share. Geographically, North America leads the revenue share due to high drug pricing and premium product adoption, while the rapid growth in the Asia-Pacific region is poised to significantly redistribute the volume-based market share over the forecast period.